



(51) International Patent Classification:

A61P 35/00 (2006.01) B82Y 5/00 (2011.01)
 A61K 47/56 (2017.01) C07D 211/22 (2006.01)
 A61K 47/60 (2017.01) C08G 83/00 (2006.01)
 A61K 49/12 (2006.01) A61K 31/445 (2006.01)
 A61K 49/14 (2006.01) C08G 69/10 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2019/056924

(22) International Filing Date:

15 August 2019 (15.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/719,319 17 August 2018 (17.08.2018) US

(71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151-85, Södertälje (SE).

(72) Inventors: GELLERT, Paul; AstraZeneca UK Limited, Charter Way, Macclesfield Cheshire SK10 2NA (GB). HILL, Kathryn; AstraZeneca UK Limited, Charter Way, Macclesfield Cheshire SK10 2NA (GB). STOREY, Richard; AstraZeneca UK Limited, Charter Way, Macclesfield Cheshire SK10 2NA (GB).

(74) Agent: STORM, Peter; Astrazeneca AB, SE-151-85, Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: DENDRIMER FORMULATIONS



(57) Abstract: Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer.